Literature DB >> 6736162

Determination of cadralazine in human plasma and urine by high-performance liquid chromatography.

S A Hauffe, J P Dubois.   

Abstract

A high-performance liquid chromatographic method is described for the determination of cadralazine in human plasma and urine. To 1 g of plasma (pH 7) or urine (adjusted to pH 11), internal standard was added and the samples were extracted with chloroform-ethanol (95:5, v/v). The substances were then back-extracted into acid (pH 2) and 100 microliter of the aqueous phase were injected. Chromatography was performed on a 10-micron LiChrosorb RP-8 column with acetonitrile-phosphate buffer pH 6 (15:85, v/v) as eluent at a flow-rate of 2.7 ml/min. The substances were detected by UV spectrophotometry at 254 nm. Concentrations down to 0.141 nmol/g in plasma or 10.59 nmol/g in urine could be measured with very good precision. This method was applied to samples from two healthy volunteers given a single oral dose of 10 mg or 20 mg of cadralazine .

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6736162     DOI: 10.1016/s0021-9673(01)93577-0

Source DB:  PubMed          Journal:  J Chromatogr


  5 in total

1.  Influence of acetylator status on the haemodynamic effects and pharmacokinetics of cadralazine in healthy subjects.

Authors:  P Brunel; J B Lecaillon; T T Guyene; P Imhof; J Ménard
Journal:  Br J Clin Pharmacol       Date:  1990-05       Impact factor: 4.335

2.  Human pharmacokinetics of cadralazine: a new vasodilator.

Authors:  S A Hauffe; J P Dubois; P R Imhof
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1985 Jul-Sep       Impact factor: 2.441

Review 3.  Cadralazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension.

Authors:  D McTavish; R A Young; S P Clissold
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

4.  Acute systemic and renal haemodynamic effects and long-term antihypertensive action of cadralazine in patients pretreated with beta-blockers and diuretics.

Authors:  B Persson; G Granerus; M Wysocki; T Hedner; O K Andersson
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

5.  Pharmacokinetics of cadralazine and its hydrazino-metabolite in patients with renal impairment after repeated administration of 5 mg once daily.

Authors:  J F Marichal; P Brunel; J B Lecaillon; J Godbillon; B Faller; P Brignon; J Ménard
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Jul-Sep       Impact factor: 2.441

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.